Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Lithium citrate
Essential Pharma M
N05AN01
Lithium citrate
104mg/1ml
Oral solution
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04020300; GTIN: 5013003900357
Découpe 1 PACKAGE LEAFLET: INFORMATION FOR THE USER PRIADEL 520MG/5ML LIQUID Lithium Citrate Is this leafl et hard to see or read? Phone 0845 372 7101 for help READ ALL OF THIS LEAFL ET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU • Keep this leafl et. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side eff ects, talk to your doctor or pharmacist. This includes any possible side eff ects not listed in this leafl et. See section 4. WHAT IS IN THIS LEAFL ET 1. What Priadel is and what it is used for 2. What you need to know before you take Priadel 3. How to take Priadel 4. Possible side eff ects 5. How to store Priadel 6. Contents of the pack and other information 1. WHAT PRIADEL IS AND WHAT IT IS USED FOR Priadel Liquid contains a medicine called lithium. This belongs to a group of medicines called mood stabilisers. It works by stabilising the levels of chemicals in your brain that aff ect your mood. Priadel can be used to manage or control: • Mania (feeling highly excited, being over-active and easily irritated or distracted). • Hypo-mania (similar to mania, but less severe). • Repeated periods of depression, where treatment with other medicines has not worked. • Aggressive or self-harming behaviour. It is also used to help prevent bipolar depression - where the mood changes between feeling very high (mania) and very low (depression). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PRIADEL DO NOT TAKE PRIADEL IF: ✕ You are allergic (hypersensitive) to lithium citrate or any of the other ingredients of Priadel (see Section 6: Further information). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue. ✕ You are breast-feeding. ✕ You have heart disease. ✕ Yo Read the complete document
OBJECT 1 PRIADEL 520MG/5ML LIQUID Summary of Product Characteristics Updated 01-Feb-2018 | SANOFI 1. Name of the medicinal product Priadel 520mg/5ml Liquid. 2. Qualitative and quantitative composition Each 5ml contains 520mg of the active substance lithium citrate equivalent to 204mg lithium carbonate. Also contains 211mg of ethanol 96%. For a full list of excipients see section 6.1. 3. Pharmaceutical form Syrup Clear, colourless, pineapple flavoured, sugar free syrup. 4. Clinical particulars 4.1 Therapeutic indications 1. In the management of acute manic or hypomanic episodes. 2. In the management of episodes of recurrent depressive disorders where treatment with other antidepressants has been unsuccessful. 3. In the prophylaxis against bipolar affective disorders. 4. Control of aggressive behaviour or intentional self-harm. 4.2 Posology and method of administration Dosage must be individualised depending on serum lithium levels and clinical response. The dosage necessary to maintain serum lithium levels within the therapeutic range varies from patient to patient. The minimum effective dose should be sought and maintained. As a general rule, the following dosing schedule is recommended. Please refer also to the specific recommendations for the different indications as listed below: 1. In patients of average weight (70kg) an initial daily dose of 10-30ml Priadel Liquid (equivalent to 408- 1224mg lithium carbonate) should be given in divided doses, ideally twice a day. When changing between lithium preparations serum lithium levels should first be checked, then Priadel Liquid therapy started at a daily dose as close as possible to the dose of the other form of lithium. As bioavailability varies from product to product (particularly with regard to slow release preparations) a change of product should be regarded as initiation of new treatment. 2. Four to a maximum of seven days after starting treatment, serum lithium levels should be measured. Optimal maintenance serum levels may vary from patient to patient. 3. Bl Read the complete document